Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-146a-5p mimic
- Development stage
- Preclinical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Transfection
01
Overview
microRNA-146a-5p mimic is a synthetic double-stranded RNA oligonucleotide designed to simulate the biological activity of the endogenous tumor-suppressive microRNA, miR-146a-5p. In various malignancies, particularly epithelial ovarian cancer, miR-146a-5p expression is frequently downregulated, which contributes to apoptosis resistance and chemoresistance. The mimic functions by binding to the 3' untranslated regions (UTRs) of target mRNAs, leading to translational inhibition or mRNA degradation. Key therapeutic targets include anti-apoptotic genes such as XIAP, BCL2L2 (Bcl-w), and BIRC5 (Survivin). By suppressing these proteins, the mimic sensitizes cancer cells to DNA-damaging agents like cisplatin, thereby enhancing the efficacy of chemotherapy and promoting programmed cell death.
- Other names
- miR-146a-5p mimicmiR146a-5p mimicmiR 146a-5p mimichsa-miR-146a-5p mimichsa-miR146a-5p mimichsa-miR 146a-5p mimicmicroRNA-146a mimicmicroRNA146a mimicmicroRNA 146a mimic
02
Targets
Baculoviral IAP repeat-containing protein 5 messenger RNA 3' untranslated regionX-linked inhibitor of apoptosis protein messenger RNA 3' untranslated regionBCL2L2 (BCL-2-like protein 2)BIRC5 (Survivin)XIAP
Beyond the preview
Go deeper on microRNA-146a-5p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA-146a-5p mimic.